Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 2
1986 2
1987 2
1988 9
1989 6
1990 42
1991 13
1992 14
1993 25
1994 20
1995 18
1996 21
1997 37
1998 42
1999 28
2000 38
2001 44
2002 33
2003 23
2004 33
2005 23
2006 29
2007 25
2008 22
2009 29
2010 30
2011 32
2012 20
2013 25
2014 25
2015 15
2016 11
2017 17
2018 23
2019 12
2020 25
2021 15
2022 10
2023 9
2024 15
2025 11
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

826 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean firestone (2,540 results)?
Toremifene citrate (Fareston).
Gerken P. Gerken P. Clin J Oncol Nurs. 2004 Oct;8(5):529-30. doi: 10.1188/04.CJON.529-530. Clin J Oncol Nurs. 2004. PMID: 15565747 No abstract available.
Experimental adenomyosis.
Greaves P, White IN. Greaves P, et al. Best Pract Res Clin Obstet Gynaecol. 2006 Aug;20(4):503-10. doi: 10.1016/j.bpobgyn.2006.01.003. Epub 2006 Feb 23. Best Pract Res Clin Obstet Gynaecol. 2006. PMID: 16500151 Review.
Its incidence in mice can be markedly enhanced by systemic exposure to various hormonal agents, including prolactin, progesterone, synthetic progestins, certain oestrogenic agents, as well as tamoxifen and toremifene. The precise hormonal changes necessary remain unclear, …
Its incidence in mice can be markedly enhanced by systemic exposure to various hormonal agents, including prolactin, progesterone, synthetic …
Toremifene.
[No authors listed] [No authors listed] IARC Monogr Eval Carcinog Risks Hum. 1996;66:367-87. IARC Monogr Eval Carcinog Risks Hum. 1996. PMID: 9097128 Free PMC article. Review. No abstract available.
Breast pain.
Goyal A. Goyal A. BMJ Clin Evid. 2011 Jan 17;2011:0812. BMJ Clin Evid. 2011. PMID: 21477394 Free PMC article.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics, bromocriptine, combined oral contraceptive pill, danazol, diuretics, evening primrose oil, gestrinone, gonadorelin analogues, hormon …
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antib …
Toxicity of antiestrogens.
Hirsimäki P, Aaltonen A, Mäntylä E. Hirsimäki P, et al. Breast J. 2002 Mar-Apr;8(2):92-6. doi: 10.1046/j.1524-4741.2002.08204.x. Breast J. 2002. PMID: 11896754 Review.
The object of this article is to review briefly the preclinical and clinical safety of some antiestrogens. Tamoxifen, toremifene, droloxifene, and idoxifene are polyphenylethylene antiestrogens, whereas the pure antiestrogen, ICI 182,780 or faslodex, as well as raloxifene, …
The object of this article is to review briefly the preclinical and clinical safety of some antiestrogens. Tamoxifen, toremifene, dro …
RETIRED: Mastalgia.
Rosolowich V, Saettler E, Szuck B; BREAST DISEASE COMMITTEE. Rosolowich V, et al. J Obstet Gynaecol Can. 2006 Jan;28(1):49-57. doi: 10.1016/S1701-2163(16)32027-8. J Obstet Gynaecol Can. 2006. PMID: 16533457 English, French.
Introduction to toremifene.
Kangas L. Kangas L. Breast Cancer Res Treat. 1990 Aug;16 Suppl:S3-7. doi: 10.1007/BF01807138. Breast Cancer Res Treat. 1990. PMID: 2149282 Review.
Toremifene, a triphenylethylene antiestrogen first synthesized in 1981, binds to the estrogen receptor with an affinity about 5% that of estradiol. ...In Phase I and Phase II clinical trials, toremifene has shown good response rates in ER-positive or ER-unknown tumo …
Toremifene, a triphenylethylene antiestrogen first synthesized in 1981, binds to the estrogen receptor with an affinity about 5% that …
Adjuvant trials of toremifene vs tamoxifen: the European experience.
Holli K. Holli K. Oncology (Williston Park). 1998 Mar;12(3 Suppl 5):23-7. Oncology (Williston Park). 1998. PMID: 9556787 Free article. Review.
When results from the phase II trials of toremifene (Fareston) and tamoxifen (Nolvadex) in metastatic breast cancer were published, the Finnish Breast Cancer Group began to plan the first trial of toremifene in an adjuvant setting. ...Toremifene seems …
When results from the phase II trials of toremifene (Fareston) and tamoxifen (Nolvadex) in metastatic breast cancer were publi …
[Hormone therapy of advanced renal cancer with high-dose toremifene (Fareston)].
Gershanovich ML, Moiseenko VM, Vorob'ev AV, Kiapiulia K. Gershanovich ML, et al. Vopr Onkol. 1996;42(5):105-9. Vopr Onkol. 1996. PMID: 9064893 Russian.
Toremifene (Fareston)-a novel antiestrogenic drug with a triphenylethylene structure-has been effective in the treatment of postmenopausal breast cancer patients. ...The purpose of the study was to investigate the effect and tolerability of high dose toremifene …
Toremifene (Fareston)-a novel antiestrogenic drug with a triphenylethylene structure-has been effective in the treatment of po …
Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ. Lewis JD, et al. Cancer. 2010 May 15;116(10):2307-15. doi: 10.1002/cncr.24940. Cancer. 2010. PMID: 20209619 Free article. Clinical Trial.
BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent treatments for metastatic breast cancer. ...METHODS: The North American Fareston versus Tamoxifen Adjuvant trial assigned 1813 perimen …
BACKGROUND: Fareston (toremifene) and tamoxifen, both selective estrogen receptor modulators, are therapeutically equivalent t …
826 results